Proteins & antibodies

Our recombinant protein and antibody capabilities include mammalian cell line generation, production, purification and analysis of recombinant proteins and antibodies manufactured in mammalian systems.

Protein and antibody capabilities

Here at Batavia Biosciences, we generate protein and antibody products as well as perform process development and scale-up of such products in our Woburn facility (MA, USA). Clinical manufacturing of all products is performed in our GMP facility located in the Netherlands. Batavia Biosciences offers unique technologies to increase protein and antibody product yields, decrease process development time, and improve product stability. In general, our strengths include vector construction, stable mammalian cell line generation, small- and large-scale transient production, upstream and downstream process development and scale-up, medium selection, feed strategy optimization, analytical development, product characterization and cGMP manufacturing. Our comprehensive expertise allows us to deliver a complete package comprising of purified product together with all relevant protocols and pivotal biochemical and analytical characterization data.

Proteins and antibodies track record

We have successfully delivered a diverse range of biosimilars including growth factors, fertility hormones, enzymes, anti-cancer fusion proteins, clotting factors, antibodies, antibody fragments, viral proteins and antigenic proteins. For instance, in collaboration with Prof. James Crowe (Pediatrics & Pathology, Microbiology & Immunology Department, Vanderbilt Vaccine Center, Nashville) we have worked on the generation of CHO cell lines expressing potent virus-neutralizing antibodies. Additionally, for COPro Biotech, we have used our STEP^® technology to develop a stable biosimilar producer cell line.

Prof. James Crowe, Vanderbilt Vaccine Center: “The proactive thinking and problem-solving mindset at Batavia have been very much appreciated. Getting our potent antibodies from bench to clinic is an absolute priority.”

Yiding Wang, Director Operations, COPro Biotech: “With pleasure we have collaborated with the Batavia team on cell line development. Their STEP^® technology is very suitable for generating biosimilar producing cell lines.”